Antisense transcription uncovers disease-linked adaptations in the human gut microbiome

A hidden layer of microbial activity in the human gut may help explain how bacterial communities adapt to inflammation, according to a study published in Nature Microbiology. Researchers report that antisense RNAs—transcripts produced from the DNA strand opposite the one used to make conventional messenger RNAs—form disease-associated programmes in people with inflammatory bowel disease (IBD). These programmes were shared across patients, linked to clinical and chemical indicators of inflammation, and connected to genetic changes that can redistribute adaptive functions through microbial populations.

The study introduces metastrand, a computational framework designed to analyse strand-specific metatranscriptomic and metagenomic data from complex microbial communities. Standard metatranscriptomics measures which genes are being transcribed, but it can overlook the direction of transcription. Metastrand instead distinguishes sense transcripts, which generally correspond to protein-coding messenger RNAs, from antisense transcripts, which are generated from the opposite DNA strand. By integrating RNA and DNA sequencing at gene-level resolution, the framework allows researchers to examine not only which microbial genes are active, but also how transcription is oriented and regulated.

Antisense transcription is widespread in bacteria, although its effects can vary considerably. An antisense RNA may bind to a complementary messenger RNA and alter its stability, interfere with translation, or influence transcription itself. In some cases, transcription from the opposite strand can modify the local DNA or RNA landscape without producing a conventional protein. Because these molecules can regulate gene expression rapidly, they may provide bacteria with a flexible mechanism for responding to stresses such as oxidative damage, nutrient limitation, immune activity or competition with neighbouring organisms.

When the researchers applied metastrand to gut microbiome samples from people with IBD, they found that antisense RNA activity was not random. During active disease, microbial antisense programmes converged across patients, suggesting that different microbial communities may activate similar regulatory strategies under inflammatory pressure. The programmes correlated with faecal metabolite profiles and concentrations of calprotectin, a protein commonly used as a non-invasive indicator of intestinal inflammation. Their association with these measurements suggests that antisense transcription could provide information about disease activity beyond what is revealed by microbial species abundance alone.

The signal also appeared to persist in individuals experiencing ongoing inflammation. This stability is important because the composition of the gut microbiome can fluctuate substantially between people and over time. A biomarker based only on the presence or absence of bacterial species may therefore be difficult to generalise. Antisense programmes, by contrast, could reflect a shared physiological response among different microbial populations. If validated in larger and independent patient cohorts, these transcriptional patterns might eventually support monitoring of inflammatory activity or treatment response.

A particularly notable finding involved insertion sequence elements, small mobile genetic elements that can move within bacterial genomes. These elements often contain transposase genes, which encode the machinery required for movement, but they may also be associated with nearby passenger genes that affect bacterial traits. The researchers observed shifts in transcription from the sense direction toward the antisense direction at insertion sequence regions. These changes occurred before the same elements were detected at new genomic locations, linking antisense dynamics to later structural genome rearrangements.

Such rearrangements can have major consequences for microbial adaptation. When an insertion sequence relocates, it may disrupt a gene, alter the activity of a neighbouring promoter or carry regulatory influences into a new genomic context. The passenger genes associated with these elements were functionally diverse, indicating that the process was not limited to a single pathway. Instead, mobile DNA may help bacteria redistribute a broad range of adaptive functions while they face selective pressures in an inflamed gut.

The researchers examined whether the phenomenon was specific to human IBD. Similar antisense responses were identified in a mouse model of colitis, in bacterial cultures exposed to oxidative stress in the laboratory and in patients with pathogen-confirmed gastroenteritis. The convergence across these settings strengthens the interpretation that antisense transcription is part of a broader microbial response to intestinal stress rather than an incidental feature of one disease cohort. Oxidative stress is particularly relevant because immune cells generate reactive molecules during inflammation, creating conditions that can damage microbial DNA, proteins and membranes.

The findings expand the way scientists view the gut microbiome. Microbial adaptation is often studied through changes in species composition, gene content or protein-coding mutations. The new work indicates that transcriptional direction itself can be a meaningful biological variable. Antisense RNAs may act as early signals of regulatory reprogramming, while their association with mobile genetic elements suggests that short-term changes in gene expression can precede longer-term genome restructuring. This provides a possible connection between immediate stress responses and the evolution of microbial communities.

The study does not yet establish whether antisense RNAs directly cause the genomic rearrangements or whether both arise from a common stress response. Further experiments will be needed to determine the molecular mechanisms involved, identify the bacterial species responsible for the strongest signals and test how reliably these programmes predict clinical outcomes. Nevertheless, metastrand offers a way to capture a previously underappreciated layer of microbiome biology. By revealing how microbes change transcriptional orientation during inflammation, the approach could help transform antisense RNAs into indicators of intestinal disease and clarify how microbial genomes adapt under pressure.